Alenson Carman Acquires Agios Pharmaceuticals Inc. (AGIO) Shares

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) finished Friday with an addition of $0.56 to close at $48.55, an upside of 1.17 percent. An average of 317,360 shares of common stock have been traded in the last five days. There was a gain of $2.27 in the past week, and it reached a new high 23 times over the past 12 months. The last 20 days have seen an average of 390,435 shares traded, while the 50-day average volume stands at 431,066.

AGIO stock has increased by 1.68% in the last month. The company shares reached their 1-month lowest point of $42.85 on 10/06/21. With the stock rallying to its 52-week high on 06/21/21, shares of the company touched a low of $32.47 and a high of $62.15 in 52 weeks. It has reached a new high 20 times so far this year and achieved 12.05% or $5.22 in price. In spite of this, the price is down -21.89% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

124 days have passed since Agios Pharmaceuticals Inc. (AGIO) last reported insider trading activity. Alenson Carman, who is Principal Accounting Officer, most recently acquired $1,777 shares at $61.61 per share on Jun 21. In this transaction, the insider spent $109,481. Chief Medical Officer, Bowden Christopher, disposed of 48,493 shares at a price of $60.11 on Jun 18. The insider now owns more than $2,914,851 worth of shares. Prior to that, Chief Medical Officer Bowden Christopher went on to Sale 2,502 shares at $60.02 each on Jun 17. An amount of $150,170 was transacted.

Valuation Metrics

Agios Pharmaceuticals Inc. (AGIO) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 33.43 for the sector. In the last five years, Agios Pharmaceuticals Inc.’s PE ratio has ranged between 2.687 and 1.847. The stock’s beta is 1.54. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 36.67, the price-to-book (PB) ratio at 1.72.

Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $200.39 million compared to revenue of $203.2 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Agios Pharmaceuticals Inc.’s return on assets was 103.90%. For the broader industry, ROE averaged -68.79 over the past year.

Earnings Surprise

The company posted a net income of -$86.22 million in the quarter, while revenues of $1.87 billion were shrunk -4.94%. The analyst consensus anticipated Agios Pharmaceuticals Inc.’s latest quarter earnings to come in at -$1.39 per share, but it turned out to be -$1.41, a -1.40% surprise. For the quarter, EBITDA amounted to -$87.11 million. Shareholders own equity worth $58.95 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Agios Pharmaceuticals Inc. (AGIO) price momentum. RSI 9-day as of the close on 22 October was 66.58%, suggesting the stock is Neutral, with historical volatility in this time frame at 37.77%.

As of today, AGIO’s price is $46.84 +4.90% or $2.27 from its 5-day moving average. AGIO is currently trading +2.17% higher than its 20-day SMA and -14.16% lower than its 100-day SMA. However, the stock’s current price level is +10.22% above the SMA50 and +4.05% above the SMA200.

The stochastic %K and %D were 95.50% and 81.73%, respectively, and the average true range (ATR) was 1.60. With the 14-day stochastic at 96.61% and the average true range at 1.56, the RSI (14) stands at 61.53%. The stock has reached 1.56 on the 9-day MACD Oscillator while the 14-day reading was at 2.47.

Analyst Ratings

Goldman downgraded Agios Pharmaceuticals Inc. (NASDAQ: AGIO) to a a Sell rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Agios Pharmaceuticals Inc. (AGIO) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell AGIO, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.

What is AGIO’s price target for the next 12 months?

Analysts predict a range of price targets between $39.00 and $93.00, with a median target of $61.00. Taking a look at these predictions, the average price target given by analysts for Agios Pharmaceuticals Inc. (AGIO) stock is $62.43.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam